Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of the National Cancer Institute

• Publication date

  2018-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/jnci/djx258PMID 29228315
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial.

  2017cited by this paper
• Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC→4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer.

  2017cited by this paper
• Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial

  2017cited by this paper
• Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69)

  2017cited by this paper
• Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.

  2017cited by this paper
• Abstract S6-03: DBCG 07-READ: A randomized phase III trial comparing six cycles of docetaxel and cyclophosphamide (DC) to three cycles of epirubicin and cyclophosphamide followed by three cycles of docetaxel (EC-D) in patients with early breast cancer

  2017cited by this paper
• Abstract P5-15-03: nab-paclitaxel + carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the tnAcity trial

  2017cited by this paper
• Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial

  2017influential reference
• Abstract S5-06: BRCA mutations, therapy response and prognosis in the neoadjuvant GeparQuinto study

  2016cited by this paper
• ETNA (Evaluating Treatment with Neoadjuvant Abraxane) randomized phase III study comparing neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) both followed by anthracycline regimens in women with HER2-negative high-risk breast cancer: A MICHELANGO study.

  2016cited by this paper
• Prognosis of triple negative breast cancer patients who attain pathological complete response with neoadjuvant carboplatin/docetaxel and do not receive adjuvant anthracycline chemotherapy.

  2016cited by this paper
• BRCA1‐like profile predicts benefit of tandem high dose epirubicin‐cyclophospamide‐thiotepa in high risk breast cancer patients randomized in the WSG‐AM01 trial

  2016cited by this paper
• Abstract S2-04: Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto)

  2016cited by this paper
• Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers

  2016cited by this paper
• Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance)

  2016cited by this paper
• Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel + cyclophosphamide (TC) v anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative br

  2016influential reference
• Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.

  2016cited by this paper
• Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts

  2016cited by this paper
• Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial

  2016cited by this paper
• Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.

  2015cited by this paper
• SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer

  2015cited by this paper
• Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.

  2015cited by this paper
• Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

  2015cited by this paper
• Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).

  2015influential reference
• Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.

  2015cited by this paper
• Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.

  2015cited by this paper
• Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: Results from GeparSixto.

  2015cited by this paper
• Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative orBRCA1/2breast cancer (CRUK/07/012)

  2015cited by this paper
• Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer: WSG-ADAPT HER2+/HR+ phase II trial.

  2015cited by this paper
• Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

  2015cited by this paper
• Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance).

  2015cited by this paper
• Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.

  2014cited by this paper
• Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

  2014influential reference
• Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

  2014cited by this paper
• Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients

  2014cited by this paper
• Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial.

  2014cited by this paper
• Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.

  2014cited by this paper
• PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients

  2014cited by this paper
• Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

  2013cited by this paper
• WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial

  2013cited by this paper
• Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort

  2013cited by this paper
• Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.

  2013influential reference
• Bevacizumab added to neoadjuvant chemotherapy for breast cancer.

  2012cited by this paper
• A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study

  2012influential reference
• Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

  2012cited by this paper
• Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group.

  2011cited by this paper
• Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer

  2010cited by this paper
• Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials

  2010cited by this paper
• Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.

  2010cited by this paper
• An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients

  2010cited by this paper
• Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study.

  2009cited by this paper
• Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.

  2009cited by this paper
• Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial.

  2008cited by this paper
• Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

  2008cited by this paper
• Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment.

  2008cited by this paper
• Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.

  2005cited by this paper
• Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer.

  2004cited by this paper

• Case Report: Pathologic complete response in triple negative breast cancer treated with anthracycline free regimen

  2026cites this paper
• Comparing efficacy of neoadjuvant therapy of triple-negative breast cancer: A Bayesian network meta-regression analysis

  2026cites this paper
• Nanoparticle albumin-bound paclitaxel (nab-Paclitaxel): Bridging pharmacology and translational medicine in breast cancer.

  2025cites this paper
• Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin for triple-negative breast cancer: a multicenter, open-label, phase II cTRIO study

  2025cites this paper
• Retrospective analysis of the clinical efficacy of neoadjuvant chemotherapy albumin paclitaxel combined with carboplatin in the treatment of triple-negative breast cancer

  2025cites this paper
• Transcriptomic and microenvironment characteristics of triple-negative breast cancer under three different neoadjuvant treatment regimens

  2025cites this paper
• New Perspectives in the Management of Triple-Negative Breast Cancer.

  2025cites this paper
• Efficacy and safety of platinum-based, anthracycline-free neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis

  2025cites this paper
• Comparative Effectiveness of Paclitaxel‐Containing Regimens for Treatment of Triple‐Negative Breast Cancer: A Network Meta‐Analysis

  2025cites this paper
• Role of imaging based response assesment for adapting neoadjuvant systemic therapy for breast cancer: A systematic review.

  2025cites this paper
• Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61-20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial.

  2025cites this paper
• Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer

  2025cites this paper
• HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN

  2025influential citation
• Revisiting surrogacy of pathological complete response for long-term survival in triple negative breast cancer.

  2025cites this paper
• Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial

  2025cites this paper
• Tumor-infiltrating lymphocytes refine outcomes in triple-negative breast cancer treated with anthracycline-free neoadjuvant chemotherapy.

  2024cites this paper
• TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy.

  2024cites this paper
• Shifting the Paradigm: The Transformative Role of Neoadjuvant Therapy in Early Breast Cancer

  2024cites this paper
• EFFECTIVENESS AND SAFETY OF PLATINUM BASED AGENTS NEOADJUVANT CHEMOTHERAPY ON PATHOLOGICAL COMPLETE RESPONSE IN TRIPLE NEGATIVE BREAST CANCER PATIENTS (A RETROSPECTIVE STUDY)

  2024influential citation
• Assessment of novel prognostic biomarkers to predict pathological complete response in patients with non-metastatic triple-negative breast cancer using a window of opportunity design

  2024cites this paper
• Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)

  2024cites this paper
• Post(neo)adjuvante Therapiekonzepte – Möglichkeiten der Individualisierung

  2024cites this paper
• Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trial

  2024cites this paper
• A Comprehensive Review on the State of the Art of Breast Cancers in Italy.

  2024cites this paper
• Impact of Homologous Recombination Deficiency on Outcomes in Patients With Triple-Negative Breast Cancer Treated With Carboplatin-Based Neoadjuvant Chemotherapy: Secondary Analysis of the NeoCART Randomized Clinical Trial

  2023cites this paper
• Prognostic predictive value of Ki-67 in stage I–II triple-negative breast cancer

  2023cites this paper
• Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial.

  2023cites this paper
• Dose-Dense Docetaxel-Cyclophosphamide and Epirubicin-Cisplatin(ddDCEP): Analysis of an Alternative Platinum-Containing Regimen in 116 Patients with Early Triple Negative Breast Cancer

  2023cites this paper
• Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP

  2023cites this paper
• An overview of the research progress of BRCA gene mutations in breast cancer.

  2023cites this paper
• Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC)

  2023cites this paper
• Prospect of neoadjuvant/adjuvant immunotherapy in early-stage triple-negative breast cancer

  2023cites this paper
• Ki67 increase after core needle biopsy associated with worse disease outcome in HER2-negative breast cancer patients

  2023cites this paper
• Nanoparticle Drug Delivery Systems and Their Applications as Targeted Therapies for Triple Negative Breast Cancer

  2023cites this paper
• Platinum‐based chemotherapy for early triple‐negative breast cancer

  2023cites this paper
• Optimization of Neoadjuvant Therapy for Early-Stage Triple-Negative and HER2 + Breast Cancer

  2022cites this paper
• Early-stage Triple-negative Breast Cancer: Time to Optimize Personalized Strategies

  2022cites this paper
• Platinum is essential in neoadjuvant treatment of triple-negative breast cancer: a network meta-analysis

  2022cites this paper
• Systemic Therapy De-Escalation in Early-Stage Triple-Negative Breast Cancer: Dawn of a New Era?

  2022cites this paper
• Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases

  2022cites this paper
• Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial.

  2022cites this paper
• Automatic data extraction to support meta-analysis statistical analysis: a case study on breast cancer

  2022cites this paper
• Lobaplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: a 5-year follow-up of a randomized, open-label, phase II trial

  2022cites this paper
• Evolving Evidence for the Optimization of Neoadjuvant Therapy in Triple-Negative Breast Cancer

  2022cites this paper
• De-escalated neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Impact of molecular markers and survival analysis of the WSG-ADAPT-TN trial.

  2022cites this paper
• Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents

  2022cites this paper
• Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial

  2022cites this paper
• Time to optimize de-escalation strategies in triple-negative breast cancer?

  2022cites this paper
• Therapie des triple-negativen Mammakarzinoms

  2022cites this paper
• Comparative efficacy and safety of first-line neoadjuvant treatments in triple-negative breast cancer: systematic review and network meta-analysis

  2022cites this paper
• Thioridazine combined with carboplatin results in synergistic inhibition of triple negative breast cancer by targeting cancer stem cells

  2022cites this paper
• Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: meta-analysis

  2022influential citation
• Platinum-based adjuvant therapy was efficient for triple-negative breast cancer: a meta-analysis from randomized controlled trials

  2022cites this paper
• Reporting of tobacco use and tobacco-related analyses in cancer cooperative group clinical trials: a systematic scoping review

  2022cites this paper
• Platinum-based systematic therapy in triple-negative breast cancer.

  2022cites this paper
• Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Pairwise and Network Meta-Analysis of Pathological Complete Response

  2021cites this paper
• Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis

  2021cites this paper
• Immuntherapie bei Brustkrebs

  2021influential citation
• Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness

  2021cites this paper
• Identifying the Effect of Ursolic Acid Against Triple-Negative Breast Cancer: Coupling Network Pharmacology With Experiments Verification

  2021cites this paper
• A Prospective, Single-Arm, Phase II Trial of Apatinib Combined With Nab-Paclitaxel and Carboplatin for The Neoadjuvant Treatment of Triple-Negative Breast Cancer

  2021cites this paper
• The choice of a neoadjuvant chemotherapy cycle for breast cancer has significance in clinical practice: results from a population-based, real world study

  2021cites this paper
• A meta-analysis of the effect and safety of platinum-based neoadjuvant chemotherapy in treatment of resectable triple-negative breast cancer

  2021cites this paper
• Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer

  2021cites this paper
• The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials

  2021cites this paper
• AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021

  2021cites this paper
• Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer

  2021cites this paper
• Can axillary surgery be omitted in patients with breast pathologic complete response after neoadjuvant systemic therapy for breast cancer? A real-world retrospective study in China

  2021cites this paper
• Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial

  2021cites this paper
• Exploring the Potential of Metallodrugs as Chemotherapeutics for Triple Negative Breast Cancer.

  2021cites this paper
• GBP5 Serves as a Potential Marker to Predict a Favorable Response in Triple-Negative Breast Cancer Patients Receiving a Taxane-Based Chemotherapy

  2021cites this paper
• Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12‐week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials

  2021cites this paper
• Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With Chemotherapy.

  2021cites this paper
• Immuntherapie bei Brustkrebs

  2021cites this paper
• Neo‐adjuvant therapy for triple‐negative breast cancer: Insights from a network meta‐analysis

  2020cites this paper
• Impact of the addition of carboplatin to anthracycline‐taxane‐based neoadjuvant chemotherapy on survival in BRCA1/2‐mutated triple‐negative breast cancer

  2020cites this paper
• Early stage triple negative breast cancer: Management and future directions.

  2020cites this paper
• Post-Neoadjuvant Gemcitabine and Cisplatin with Regional Hyperthermia for Patients with Triple-Negative Breast Cancer and Non-pCR after Neoadjuvant Chemotherapy: A Single-Institute Experience

  2020cites this paper
• Platinum-based drugs in neoadjuvant treatment of patients with triple-negative breast cancer

  2020cites this paper
• Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges

  2020influential citation
• Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer

  2020cites this paper
• Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report

  2020cites this paper
• Triple-negatives Mammakarzinom – neue Behandlungsstrategien

  2020cites this paper
• Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP)

  2020cites this paper
• Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials

  2020cites this paper
• Combination of pegylated liposomal doxorubicin and docetaxel as neoadjuvant therapy for breast cancer with axillary lymph node metastasis

  2020cites this paper
• Triple-negative breast cancer: recent treatment advances

  2019cites this paper
• Update Breast Cancer 2019 Part 1 – Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer

  2019cites this paper
• Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers.

  2019cites this paper
• Update Mammakarzinom 2019 Teil 1 – Implementierung der Ergebnisse neuer Studienkonzepte beim frühen Mammakarzinom in die klinische Praxis

  2019cites this paper
• Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple‐negative early breast cancer: Primary translational analysis of the WSG‐ADAPT‐TN trial

  2019influential citation
• Update Mammakarzinom 2019 Teil 1 – Implementierung der Ergebnisse neuer Studienkonzepte beim frühen Mammakarzinom in die klinische Praxis

  2019cites this paper
• A Review of Local and Systemic Therapy in Breast Cancer

  2019cites this paper
• The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis

  2019cites this paper
• Efficacy of two-weekly nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy for breast cancer.

  2019cites this paper
• Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice

  2019cites this paper
• NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto.

  2019cites this paper
• Post-Neoadjuvant Therapy

  2019cites this paper
• Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review

  2019cites this paper
• Diagnostik und Therapie des triple-negativen Mammakarzinoms (TNBC) – Empfehlungen für die tägliche Routine

  2019cites this paper